VIENNA, Austria — Compared with subcutaneous interferon β-1a (IFNB-1a; Rebif/EMD Serono/Pfizer), treatment with alemtuzumab (Lemtrada, Genzyme/Sanofi) improved visual outcomes in treatment-naive ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The LYNX-2 study is being conducted under conditions of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results